EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer

Otto Metzger, Sumithra Mandrekar, Shom Goel, Joseph Gligorov, Elgene Lim, Eva Ciruelos, Sibylle Loibl, Travis Dockter, Xavier Gonzàlez Farré, Prudence A Francis, Filipa Lynce, Jane Lanzillotti und 27 weitere

New England Journal of Medicine · 29.01.2026 · 394 (5) · 451-462

DOI: 10.1056/nejmoa2511218 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 29.01.2026. Verfasst von Otto Metzger und 38 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Piperazines. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Pfizer Foundation, Breast Cancer Trials, Alliance Foundation Trials.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesPiperazinesProtein Kinase InhibitorsPyridinesBreast Neoplasms, MaleAdultAgedAged, 80 and overFemaleHumansMiddle AgedCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Progression-Free SurvivalReceptors, EstrogenDrug Resistance, NeoplasmAntineoplastic Agents, HormonalMaintenance ChemotherapyNeutropeniaMaleFollow-Up Studies

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanpalbociclibPiperazinesProtein Kinase InhibitorsPyridinesReceptors, EstrogenAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Harvard Medical School, Boston.
  • Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, MN.
  • Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Institut Universitaire de Cancérologie, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Tenon Hospital and INSERM Unité 938, Paris.
  • Unicancer Breast Group, Paris.
  • Garvan Institute of Medical Research, Sydney.

ORCID-Profile: Lisa A Carey

Förderung

  • Pfizer Foundation
  • Breast Cancer Trials
  • Alliance Foundation Trials
  • German Breast Group
  • Fondazione Michelangelo
  • SOLTI
  • PrECOG
  • Unicancer

Zitieren

APA

Metzger, O., Mandrekar, S., Goel, S., Gligorov, J., Lim, E., Ciruelos, E., Loibl, S., Dockter, T., Gonzàlez Farré, X., Francis, P. A., Lynce, F., Lanzillotti, J., DuFrane, C., Wall, A., Strand, C., Krop, I., Vaz-Luis, I., Tripathy, D., Loi, S., …, & Carey, L. A. (2026). Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer. New England Journal of Medicine, 394(5), 451-462. https://doi.org/10.1056/nejmoa2511218

Vancouver

Metzger O, Mandrekar S, Goel S, Gligorov J, Lim E, Ciruelos E, et al. Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer. New England Journal of Medicine. 2026;394(5):451-462. doi:10.1056/nejmoa2511218

BibTeX
@article{Metzger2026,
  author = {Metzger, Otto and Mandrekar, Sumithra and Goel, Shom and Gligorov, Joseph and Lim, Elgene and Ciruelos, Eva and Loibl, Sibylle and Dockter, Travis and Gonzàlez Farré, Xavier and Francis, Prudence A and Lynce, Filipa and Lanzillotti, Jane and DuFrane, Carter and Wall, Anna and Strand, Carrie and Krop, Ian and Vaz-Luis, Ines and Tripathy, Debu and Loi, Sherene and Prat, Aleix and Goetz, Matthew and Escrivá-de-Romaní, Santiago and Porter, David and Spoenlein, Jennifer and Stover, Daniel G and Sardesai, Sagar and Heudel, Pierre and Koehler, Maria and Huang Bartlett, Cynthia and Holynskyj, Ariadna and Gopalakrishna, Prashanth and Gauthier, Eric and Delaloge, Suzette and Miller, Kathy and Winer, Eric P and Gianni, Luca and Partridge, Ann H and DeMichele, Angela and Carey, Lisa A},
  title = {Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {5},
  pages = {451--462},
  doi = {10.1056/nejmoa2511218}
}
Kostenlos starten →